BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11 Mutations

Press/Media

Period9 Mar 2023

Media coverage

1

Media coverage

  • TitleBerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11 Mutations
    Media name/outletCision Nordic Companies Press Releases (Scandinavia)
    Country/TerritoryDenmark
    Date9/03/23
    PersonsRajwanth Veluswamy
View all 1
View less